- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
2 result(s) found for: Pharmacoepidemiology.
Displaying page 1 of 1.
EudraCT Number: 2017-005100-99 | Sponsor Protocol Number: TYH2018307 | Start Date*: 2018-06-14 |
Sponsor Name:Helsinki University and University Hospital | ||
Full Title: Pharmacoepidemiology and pharmacogenetics of antidepressant treatment for depressive disorders (PEGAD) | ||
Medical condition: Depression (ICD-10 F32 and F33). Clinically diagnosed depression (F32-33), with symptom severity equaling or exceeding score 10 in the Patient Health Questionnaire (PHQ-9) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004939-39 | Sponsor Protocol Number: GS-EU-174-1403 | Start Date*: 2015-05-26 | |||||||||||
Sponsor Name:Gilead Sciences International Ltd. | |||||||||||||
Full Title: Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
